|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2004
|
|
gptkbp:ATCCode
|
L01EB02
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:brand
|
gptkb:Tarceva
|
|
gptkbp:CASNumber
|
183321-74-6
|
|
gptkbp:category
|
small molecule
antineoplastic agent
quinazoline
|
|
gptkbp:chemicalFormula
|
C22H23N3O4
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Roche
gptkb:OSI_Pharmaceuticals
|
|
gptkbp:drugInteraction
|
gptkb:proton_pump_inhibitors
gptkb:warfarin
CYP3A4 inhibitors
|
|
gptkbp:eliminationHalfLife
|
36 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
erlotinib
|
|
gptkbp:IUPACName
|
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
|
|
gptkbp:KEGGID
|
D04001
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
EGFR inhibitor
|
|
gptkbp:MedlinePlusID
|
a605010
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
393.44 g/mol
|
|
gptkbp:patentExpired
|
2020 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
93%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
176870
DB00530
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
anorexia
fatigue
rash
|
|
gptkbp:target
|
gptkb:epidermal_growth_factor_receptor
|
|
gptkbp:UNII
|
N2UJM5DNAK
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
pancreatic cancer
|
|
gptkbp:bfsParent
|
gptkb:EGFR
gptkb:EGFR_gene
gptkb:P15056
gptkb:P42338
gptkb:CYP3A5
gptkb:EGFR_signaling_pathway
gptkb:CYP3A4_gene
|
|
gptkbp:bfsLayer
|
6
|